- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| TRANSCODE THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 06.01. | Transcode Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 22.12.25 | TransCode Therapeutics appoints Jack E. Stover to board of directors | 2 | Investing.com | ||
| 22.12.25 | Transcode Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 11.12.25 | TransCode Therapeutics, Inc.: TransCode Therapeutics and Quantum Leap Healthcare Collaborative Launch a Phase 2a dose-expansion trial with TTX-MC138, following positive readouts from TransCode's Phase 1 trial | 190 | PR Newswire | BOSTON, Dec. 11, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ) and Quantum Leap Healthcare Collaborative ("Quantum Leap") today announce a new collaboration to evaluate... ► Artikel lesen | |
| 11.12.25 | Transcode Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 17.11.25 | TransCode Therapeutics appoints Michel Janicot as development officer | 1 | Investing.com | ||
| 27.10.25 | Transcode Therapeutics ändert Bedingungen für Vorzugsaktien nach Aktionärszustimmung | 3 | Investing.com Deutsch | ||
| 27.10.25 | Transcode Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 14.10.25 | Transcode Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 14.10.25 | TransCode Therapeutics, Inc.: TransCode Therapeutics presents preliminary data from its completed Phase 1a study with TTX-MC138 in metastatic disease at ESMO | 228 | PR Newswire | Safety primary endpoint achieved
Median treatment duration of 4 months with a range of 2 to 12 months and three patients remain on trial
RECIST data with... ► Artikel lesen | |
| 08.10.25 | TransCode Therapeutics Stock Jumps 21% On Polynoma Acquisition | 2 | RTTNews | ||
| 08.10.25 | TransCode Therapeutics stock soars after Polynoma acquisition | 3 | Investing.com | ||
| 08.10.25 | TransCode Therapeutics, Inc.: TransCode Therapeutics (RNAZ) announces the acquisition of Polynoma and a $25 Million strategic financing by a subsidiary of CK Life Sciences to form a first-in-class unique immuno-oncology ... | 229 | PR Newswire | TransCode acquires 100% of the issued and outstanding interests of Polynoma from CK Life Sciences
Concurrent equity investment of $25 Million from CK Life Sciences... ► Artikel lesen | |
| 03.10.25 | Transcode Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 02.09.25 | Transcode Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 08.05.25 | TransCode Therapeutics, Inc.: TransCode Therapeutics Successfully Completes Initial Dosing of Patients in Cohort 4 of Phase 1a Clinical Trial; No Dose Limiting Toxicities Reported | 307 | PR Newswire | 15 patients treated across four escalating dose levels of TTX-MC138
No significant safety or dose limiting toxicities reported
10 patients remain on study with... ► Artikel lesen | |
| 05.05.25 | TransCode Therapeutics, Inc.: TransCode Therapeutics Announces Effective Date for 1-for-28 Reverse Stock Split | 388 | PR Newswire | BOSTON, May 5, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) ("TransCode" or the "Company"), the RNA Oncology Company committed to more effectively... ► Artikel lesen | |
| 02.05.25 | TransCode Therapeutics, Inc.: TransCode Therapeutics Announces 1-for-28 Reverse Stock Split | 231 | PR Newswire | Split designed to achieve compliance with Nasdaq minimum bid price requirements
BOSTON, May 2, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ)... ► Artikel lesen | |
| 01.05.25 | TransCode Therapeutics, Inc.: TransCode Therapeutics Reports Further Progress on Phase 1a Clinical Trial with No Dose Limiting Toxicities Reported in Patients with Metastatic Cancer | 180 | PR Newswire | A total of 13 patients treated with four escalating doses of TTX-MC138
No significant safety or dose limiting toxicities reported
Two patients have so far maintained... ► Artikel lesen | |
| 27.03.25 | TransCode Therapeutics, Inc.: TransCode Therapeutics Announces Initial Dosing in Fourth Cohort of Phase 1 Clinical Trial with TTX-MC138 | 301 | PR Newswire | First patient in Cohort four has been treated with TTX-MC138
Ten patients have been treated with TTX-MC138 at escalating dose levels
Additional patients being... ► Artikel lesen |
1 2 Weiter >>
24 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 92,15 | -1,92 % | Moderna mit Kurssprung, auch BioNTech stark - das ist der Grund | Die Aktie von Moderna hat am Dienstag einen kräftigen Kurssprung hingelegt. Mit einem Plus von gut 17 Prozent ging das Papier aus dem US-Handel. Auch die Aktie des deutschen Konkurrenten BioNTech konnte... ► Artikel lesen | |
| QIAGEN | 39,565 | -3,07 % | QIAGEN - hält was es verspricht | Das Unternehmen aus Hilden hat seine Prognosen im abgelaufenen Geschäftsjahr erreicht. Nun geht es optimistisch in das neue Jahr, in dem es sich auf die Förderung der Produktvermarktung, regulatorische... ► Artikel lesen | |
| NOVAVAX | 6,645 | -3,60 % | NOVAVAX INC unter Beobachtung - Fokus auf Substanz | ||
| PALATIN TECHNOLOGIES | 17,990 | +8,64 % | Palatin Technologies, Inc.: Palatin Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update | Significant progress on multiple fronts - obesity pipeline advancing towards the clinic, out-licensing collaboration, strengthened balance sheet, and reinstatement... ► Artikel lesen | |
| BRAIN BIOTECH | 2,400 | -1,64 % | BRAIN Biotech: Erhebliche Veränderungen | Zehn Jahre Börsenlisting - diese runde Zahl gibt es am 9. Februar 2026 für BRAIN Biotech aus Zwingenberg in Südhessen. Trotz der rasanten Performance in den ersten beiden Jahren nach dem IPO: Summa... ► Artikel lesen | |
| VIVOSIM LABS | 1,220 | -100,00 % | VivoSim Labs, Inc.: VivoSim Labs Appoints Amar Sethi, M.D., Ph.D. as Chief Scientific Officer | SAN DIEGO, Jan. 06, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company" or "VivoSim Labs"), a pharmaceutical and biotechnology services company that is focused on providing testing... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 1,340 | +1,52 % | INOVIO Pharmaceuticals, Inc.: FDA Accepts for Review INOVIO's BLA for INO-3107 for the Treatment of Adults with Recurrent Respiratory Papillomatosis (RRP) | PLYMOUTH MEETING, Pa., Dec. 29, 2025 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help... ► Artikel lesen | |
| COSCIENS BIOPHARMA | 1,600 | -4,76 % | COSCIENS Biopharma Inc. Announces Leadership Change | TORONTO, ONTARIO, Nov. 14, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (FINRA: CSCIF) ("COSCIENS" or the "Company"), a life science company focused on natural ingredients and pharmaceutical... ► Artikel lesen | |
| XOMA ROYALTY | 22,400 | -9,68 % | XOMA Royalty Corporation: XOMA Royalty Announces CFO Transition | EMERYVILLE, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation ("XOMA Royalty") (Nasdaq: XOMA) announced today its Chief Financial Officer, Thomas Burns, will be stepping down from... ► Artikel lesen | |
| PHIO PHARMACEUTICALS | 1,140 | +0,88 % | Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Announces Participation in the Sidoti Micro-Cap Virtual Investor Conference January 21-22, 2026 | King of Prussia, Pennsylvania--(Newsfile Corp. - January 15, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its... ► Artikel lesen | |
| MOSAIC IMMUNOENGINEERING | - | - | Mosaic ImmunoEngineering Inc. - 10-Q, Quarterly Report | ||
| ORAGENICS | 0,949 | +2,03 % | Oragenics Q2 2025 Shareholder Update | Advancing Brain-First Recovery Platform Toward Clinical MilestonesPioneering Intranasal Therapeutics for Concussion SARASOTA, Fla., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American:... ► Artikel lesen | |
| LADRX | - | - | LadRx Corp - 8-K, Current Report | ||
| TENAX THERAPEUTICS | 2,770 | -100,00 % | Tenax Therapeutics, Inc.: Tenax Therapeutics Announces Result of Prespecifed Blinded Sample Size Assessment | Planned Review of Standard Deviation Demonstrates No Need to Increase Size of Ongoing LEVEL Study LEVEL On Track to Complete Enrollment in First Half of 2026; Topline Data Expected in Second Half... ► Artikel lesen | |
| BIOLINERX | 2,590 | +16,14 % | BioLineRx Ltd.: BioLineRx Reports Third Quarter 2025 Financial Results and Provides Corporate Update | - Establishes joint venture with Hemispherian AS to advance GLIX1, a first-in-class, oral, small molecule targeting DNA damage response in glioblastoma and other... ► Artikel lesen |
Das Unternehmen TRANSCODE THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,190 (-2,15 %) liegt der Kurs bei 8,640 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TRANSCODE THERAPEUTICS INC finden Sie auf Wallstreet Online.